Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells

Maria Manuela Rosado, Maria Ester Bernardo, Marco Scarsella, Antonella Conforti, Ezio Giorda, Simone Biagini, Simona Cascioli, Francesca Rossi, Isabella Guzzo, Marina Vivarelli, Luca Dello Strologo, Francesco Emma, Franco Locatelli, Rita Carsetti

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Bone marrow (BM)-derived mesenchymal stromal cells (MSCs), endowed with immunosuppressive and anti-inflammatory properties, represent a promising tool in immunoregulatory and regenerative cell therapy. Clarifying the interactions between MSCs and B-lymphocytes may be crucial for designing innovative MSC-based strategies in conditions in which B cells play a role, including systemic lupus erythematosus (SLE) and rejection of kidney transplantation. In this study, we show that, both in healthy subjects and in patients, in vitro B-cell proliferation, plasma-cell differentiation, and antibody production are inhibited by BM-derived MSCs when peripheral blood lymphocytes are stimulated with CpG, but not when sorted B cells are cultured with MSCs+CpG. Inhibition is restored in CpG+MSC cocultures when sorted T cells are added to sorted B cells, suggesting that this effect is mediated by T cells, with both CD4+ and CD8+ cells playing a role. Moreover, cell-cell contact between MSCs and T cells, but not between MSCs and B cells, is necessary to inhibit B-cell proliferation. Thus, the presence of functional T cells, as well as cell-cell contact between MSCs and T cells, are crucial for B-cell inhibition. This information can be relevant for implementing MSC-based therapeutic immune modulation in patients in whom T-cell function is impaired.

Original languageEnglish
Pages (from-to)93-103
Number of pages11
JournalStem Cells and Development
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Mesenchymal Stromal Cells
Antibody Formation
B-Lymphocytes
Cell Proliferation
T-Lymphocytes
Bone Marrow
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Coculture Techniques
Plasma Cells
Systemic Lupus Erythematosus
Kidney Transplantation
Cell Differentiation
Healthy Volunteers
Anti-Inflammatory Agents
Lymphocytes

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Hematology

Cite this

Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. / Rosado, Maria Manuela; Bernardo, Maria Ester; Scarsella, Marco; Conforti, Antonella; Giorda, Ezio; Biagini, Simone; Cascioli, Simona; Rossi, Francesca; Guzzo, Isabella; Vivarelli, Marina; Dello Strologo, Luca; Emma, Francesco; Locatelli, Franco; Carsetti, Rita.

In: Stem Cells and Development, Vol. 24, No. 1, 01.01.2015, p. 93-103.

Research output: Contribution to journalArticle

@article{5e50a82bf1774192b7a1baf3e0f5635e,
title = "Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells",
abstract = "Bone marrow (BM)-derived mesenchymal stromal cells (MSCs), endowed with immunosuppressive and anti-inflammatory properties, represent a promising tool in immunoregulatory and regenerative cell therapy. Clarifying the interactions between MSCs and B-lymphocytes may be crucial for designing innovative MSC-based strategies in conditions in which B cells play a role, including systemic lupus erythematosus (SLE) and rejection of kidney transplantation. In this study, we show that, both in healthy subjects and in patients, in vitro B-cell proliferation, plasma-cell differentiation, and antibody production are inhibited by BM-derived MSCs when peripheral blood lymphocytes are stimulated with CpG, but not when sorted B cells are cultured with MSCs+CpG. Inhibition is restored in CpG+MSC cocultures when sorted T cells are added to sorted B cells, suggesting that this effect is mediated by T cells, with both CD4+ and CD8+ cells playing a role. Moreover, cell-cell contact between MSCs and T cells, but not between MSCs and B cells, is necessary to inhibit B-cell proliferation. Thus, the presence of functional T cells, as well as cell-cell contact between MSCs and T cells, are crucial for B-cell inhibition. This information can be relevant for implementing MSC-based therapeutic immune modulation in patients in whom T-cell function is impaired.",
author = "Rosado, {Maria Manuela} and Bernardo, {Maria Ester} and Marco Scarsella and Antonella Conforti and Ezio Giorda and Simone Biagini and Simona Cascioli and Francesca Rossi and Isabella Guzzo and Marina Vivarelli and {Dello Strologo}, Luca and Francesco Emma and Franco Locatelli and Rita Carsetti",
year = "2015",
month = "1",
day = "1",
doi = "10.1089/scd.2014.0155",
language = "English",
volume = "24",
pages = "93--103",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells

AU - Rosado, Maria Manuela

AU - Bernardo, Maria Ester

AU - Scarsella, Marco

AU - Conforti, Antonella

AU - Giorda, Ezio

AU - Biagini, Simone

AU - Cascioli, Simona

AU - Rossi, Francesca

AU - Guzzo, Isabella

AU - Vivarelli, Marina

AU - Dello Strologo, Luca

AU - Emma, Francesco

AU - Locatelli, Franco

AU - Carsetti, Rita

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Bone marrow (BM)-derived mesenchymal stromal cells (MSCs), endowed with immunosuppressive and anti-inflammatory properties, represent a promising tool in immunoregulatory and regenerative cell therapy. Clarifying the interactions between MSCs and B-lymphocytes may be crucial for designing innovative MSC-based strategies in conditions in which B cells play a role, including systemic lupus erythematosus (SLE) and rejection of kidney transplantation. In this study, we show that, both in healthy subjects and in patients, in vitro B-cell proliferation, plasma-cell differentiation, and antibody production are inhibited by BM-derived MSCs when peripheral blood lymphocytes are stimulated with CpG, but not when sorted B cells are cultured with MSCs+CpG. Inhibition is restored in CpG+MSC cocultures when sorted T cells are added to sorted B cells, suggesting that this effect is mediated by T cells, with both CD4+ and CD8+ cells playing a role. Moreover, cell-cell contact between MSCs and T cells, but not between MSCs and B cells, is necessary to inhibit B-cell proliferation. Thus, the presence of functional T cells, as well as cell-cell contact between MSCs and T cells, are crucial for B-cell inhibition. This information can be relevant for implementing MSC-based therapeutic immune modulation in patients in whom T-cell function is impaired.

AB - Bone marrow (BM)-derived mesenchymal stromal cells (MSCs), endowed with immunosuppressive and anti-inflammatory properties, represent a promising tool in immunoregulatory and regenerative cell therapy. Clarifying the interactions between MSCs and B-lymphocytes may be crucial for designing innovative MSC-based strategies in conditions in which B cells play a role, including systemic lupus erythematosus (SLE) and rejection of kidney transplantation. In this study, we show that, both in healthy subjects and in patients, in vitro B-cell proliferation, plasma-cell differentiation, and antibody production are inhibited by BM-derived MSCs when peripheral blood lymphocytes are stimulated with CpG, but not when sorted B cells are cultured with MSCs+CpG. Inhibition is restored in CpG+MSC cocultures when sorted T cells are added to sorted B cells, suggesting that this effect is mediated by T cells, with both CD4+ and CD8+ cells playing a role. Moreover, cell-cell contact between MSCs and T cells, but not between MSCs and B cells, is necessary to inhibit B-cell proliferation. Thus, the presence of functional T cells, as well as cell-cell contact between MSCs and T cells, are crucial for B-cell inhibition. This information can be relevant for implementing MSC-based therapeutic immune modulation in patients in whom T-cell function is impaired.

UR - http://www.scopus.com/inward/record.url?scp=84919782445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919782445&partnerID=8YFLogxK

U2 - 10.1089/scd.2014.0155

DO - 10.1089/scd.2014.0155

M3 - Article

C2 - 25036865

AN - SCOPUS:84919782445

VL - 24

SP - 93

EP - 103

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 1

ER -